Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Biohit Oyj (HEL:BIOBV) just released its annual report and things are looking bullish. Results were good overall, with revenues beating analyst predictions by 5.6% to hit €13m. Statutory earnings per share (EPS) came in at €0.12, some 9.1% above whatthe analyst had expected. The analyst typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analyst has changed their earnings models, following these results.

View our latest analysis for Biohit Oyj

Following the latest results, Biohit Oyj's one analyst are now forecasting revenues of €15.3m in 2024. This would be a solid 17% improvement in revenue compared to the last 12 months. In the lead-up to this report, the analyst had been modelling revenues of €14.1m and earnings per share (EPS) of €0.11 in 2024. What's really interesting is that while the consensus made a small lift in revenue estimates, it no longer provides an earnings per share estimate. This suggests that revenues are now the focus of the business after this latest result.

We'd also point out that thatthe analyst has made no major changes to their price target of €2.40.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analyst is definitely expecting Biohit Oyj's growth to accelerate, with the forecast 17% annualised growth to the end of 2024 ranking favourably alongside historical growth of 6.0% per annum over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 14% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Biohit Oyj is expected to grow at about the same rate as the wider industry.

The Bottom Line

The most important thing to take away is that the analyst upgraded their revenue estimates for next year. There was also an upgrade to revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

One Biohit Oyj broker/analyst has provided estimates out to 2026, which can be seen for free on our platform here.

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Biohit Oyj (1 makes us a bit uncomfortable) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.